Kidney Cancer: S0931 (Iowa Cancer Specialists)

SWOG S0931 - EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Objective

The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. The current standard treatment after surgery is careful monitoring with no immediate treatment.

Studies suggest that one way kidney cancer may grow is through chemical signaling through a protein named “mTOR.” Everolimus is a drug that stops signaling through mTOR and may therefore stop the growth of kidney cancer. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer. It is considered investigational for use after surgery. In this study, patients will get either everolimus or placebo (a pill with no medication).

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Kidney Cancer
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email